Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00320736 · ClinicalTrials.gov registry record · Phase 4
Galantamine for Cognition in People With Schizophrenia
A Phase 4 study of Schizophrenia and Schizoaffective Disorder, sponsored by North Suffolk Mental Health Association.
- Completed
- Registry status
- Phase 4
- Development phase
- 20
- Enrollment target
- 1
- Study location
NCT00320736 is a Phase 4 study of Schizophrenia and Schizoaffective Disorder that has completed, run by North Suffolk Mental Health Association. The registered enrollment target is 20 participants, below the 219-participant average among 315 other Schizophrenia trials with a reported enrollment target (91% lower). The trial reports 1 study location across 1 state.
The verdict
NCT00320736, a Phase 4 study of Schizophrenia and Schizoaffective Disorder, has completed, sponsored by North Suffolk Mental Health Association.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 20 participants
- Enrollment target
- 1
- Study location
Study Summary
This study is a double-blind, placebo-controlled trial of the nicotinic receptor agonist, galantamine, for the improvement of memory and attention in people with schizophrenia and schizoaffective disorder. Twenty subjects on a stable dose of antipsychotic medications receive galantamine or identical placebo tablets for 8 weeks. Adverse events are screened for every week. Tests of memory, attention, and reward responsivity are performed at baseline and afer 8 weeks on medication. Clinical scales rating psychiatric symptoms are performed at the beginning, middle, and end of the trial.
Conditions Studied
Interventions
- DRUG galantamine
Study Locations (1)
Massachusetts
- Freedom Trail Clinic - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2004-01 |
| Est. Completion | 2006-05 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00320736
The ClinicalTrials.gov registry entry for NCT00320736 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 219-participant average among 315 other Schizophrenia trials with a reported enrollment target (91% lower). The listed sponsor is North Suffolk Mental Health Association, which has 11 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Schizophrenia appearing as the primary indexed condition, and to 1 intervention - of which galantamine is the first listed.
NCT00320736 reports 1 study location spanning 1 distinct geographic area - top geographies include Massachusetts.
Frequently Asked Questions
What is clinical trial NCT00320736 about?
NCT00320736 is a clinical study titled "Galantamine for Cognition in People With Schizophrenia". This study is a double-blind, placebo-controlled trial of the nicotinic receptor agonist, galantamine, for the improvement of memory and attention in people with schizophrenia and schizoaffective disorder. Twenty subjects on a stable dose of antipsychotic medications receive galantamine or identical...
What is the current status of trial NCT00320736?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 20 participants. The study started on 2004-01. Estimated completion is 2006-05.
What conditions does trial NCT00320736 study?
This clinical trial studies the following conditions: Schizophrenia, Schizoaffective Disorder.
What interventions are being tested in trial NCT00320736?
The interventions under investigation include: galantamine (DRUG).
Who is sponsoring clinical trial NCT00320736?
This trial is sponsored by North Suffolk Mental Health Association, which has 11 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00320736 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Schizophrenia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Metabolic Effects of Adjunctive Lumateperone Treatment in Clozapine-Treated Patients With Schizophrenia
RECRUITING · Phase 4
-
A Study to Evaluate the Effectiveness of Valbenazine in Adult Participants With Tardive Dyskinesia (TD) Who Remain Symptomatic While Receiving or After Stopping a Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor
RECRUITING · Phase 4
-
CLOZAPINE Response in Biotype-1
RECRUITING · Phase 4
-
Smoking Cessation With Varenicline in Schizophrenia: Antipsychotic-Induced Neurological Symptoms as Correlates
RECRUITING · Phase 4
-
Clozapine for the Prevention of Violence in Schizophrenia: a Randomized Clinical Trial
RECRUITING · Phase 4
-
Anti-Inflammatory Challenge in Schizophrenia
RECRUITING · Phase 4
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.